Scope
NICE guideline NG71 covers the diagnosis and management of Parkinson's disease in adults. Its recommendations date from 2006 and 2017, and it also refers to later technology appraisals. It covers communication and care planning, specialist diagnosis and which diagnostic tests not to use, and first-line and adjuvant drug treatment of motor symptoms. It addresses recognition of risk factors for impulse control disorders, along with information, monitoring and management. It covers drug treatment of non-motor symptoms, including sleep problems, orthostatic hypotension, psychosis, dementia and drooling. It also covers neuroprotection, therapy and nutrition services, advanced disease options and palliative care. Recommendation wording such as offer, consider and do not offer reflects the strength of each recommendation.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Suspicion, referral and diagnosis
- Suspect Parkinson's disease when a person presents with tremor, stiffness, slowness, balance problems or gait disturbance. Refer them quickly, and before starting treatment, to a specialist experienced in differential diagnosis. [1]
- Make the diagnosis clinically using the UK Parkinson's Disease Society Brain Bank criteria. Review the diagnosis every 6 to 12 months, and reconsider it if atypical features emerge. [1]
- Consider FP-CIT SPECT for people with tremor when essential tremor cannot be distinguished clinically from parkinsonism. The test should be available to specialists with expertise in its use and interpretation. [1]
- Several tests should not be used in differential diagnosis. Do not use PET, MR volumetry or objective smell testing outside clinical trials. Do not use MR spectroscopy or acute levodopa or apomorphine challenge tests at all. Structural MRI should not be used to diagnose Parkinson's disease, but may be considered when other parkinsonian syndromes are in the differential. [1]
Communication, care planning and medicine continuity
- People with Parkinson's disease may develop cognitive impairment, communication problems or depression. For this reason, give them individually tailored oral and written communication throughout the illness, reinforced as needed. Agree a comprehensive care plan with the person, their carers and specialist providers. Offer an accessible point of specialist contact, such as a Parkinson's disease nurse specialist. Tell carers about their right to a carer assessment and to an assessment for respite care. [1]
- Do not withdraw antiparkinsonian drugs abruptly. Do not let them fail suddenly through poor absorption (for example, gastroenteritis or abdominal surgery), because of the risk of acute akinesia or neuroleptic malignant syndrome. Do not use 'drug holidays'. For people admitted to hospital or care homes, give medicines at the appropriate times, which may mean allowing self-medication. Adjust them only by, or after discussion with, a Parkinson's specialist. [1]
Drug treatment of motor symptoms
- Before starting treatment, discuss the person's clinical circumstances, their lifestyle, preferences, needs and goals, and the benefits and harms of each drug class. Offer levodopa in early disease when motor symptoms affect quality of life. If they do not, consider a choice of dopamine agonist, levodopa or MAO-B inhibitor. [1]
- Do not offer ergot-derived dopamine agonists first line. Prefer non-ergot agonists in most cases, because ergot agents need monitoring. Consider an ergot agonist only as an adjunct to levodopa when dyskinesia or motor fluctuations have developed despite optimal levodopa therapy and a non-ergot agonist has not given adequate control. [1]
- When starting treatment, give oral and written information about three risks and record that the discussion took place. The risks are impulse control disorders with any dopaminergic drug, excessive sleepiness and sudden sleep onset with agonists, and psychotic symptoms with all treatments. Impulse control disorders and psychosis carry a higher risk with dopamine agonists. [1]
- If dyskinesia or motor fluctuations develop, including wearing-off, get specialist advice before changing therapy. When these occur despite optimal levodopa therapy, first discuss the person's clinical circumstances (symptoms, comorbidities, polypharmacy risks), their lifestyle, preferences, needs and goals, and the benefits and harms of each drug class. Then offer a choice of adjunct: a dopamine agonist, an MAO-B inhibitor or a COMT inhibitor. Consider amantadine when dyskinesia is not controlled by adjusting existing therapy. Do not offer anticholinergics to people with dyskinesia or motor fluctuations. [1]
Impulse control disorders
- Impulse control disorders can arise with any dopaminergic therapy at any stage of the disease. The risk is higher with dopamine agonist therapy, a history of impulsive behaviour, and a history of alcohol consumption or smoking. [1]
- When starting dopamine agonist therapy, give the person and carers oral and written information and record that the discussion took place. Explain the increased risk of impulse control disorders and that these may be concealed. Describe the types involved, such as compulsive gambling, hypersexuality, binge eating and obsessive shopping. Discuss and document impulse control disorders at review appointments, particularly when modifying therapy. [1]
- For a problematic impulse control disorder, get specialist advice before changing dopaminergic therapy. First reduce any dopamine agonist gradually, and monitor both the behaviour and any agonist withdrawal symptoms. If modifying dopaminergic therapy is not effective, offer specialist cognitive behavioural therapy targeted at the disorder. [1]
Drug management of non-motor symptoms
- At diagnosis, advise drivers to inform the DVLA and their insurer. People with daytime sleepiness or sudden sleep onset should not drive, should notify the DVLA and should consider occupational hazards. Adjust medicines after specialist advice. Consider modafinil only after a detailed sleep history has excluded reversible causes, with specialist review at least every 12 months. Modafinil should not be taken in pregnancy or when pregnancy is planned. [1]
- In people with sleep disturbance, look actively for restless legs and REM sleep behaviour disorder. Consider clonazepam or melatonin for REM sleep behaviour disorder once a medicines review has addressed drug causes. For nocturnal akinesia, consider levodopa or an oral dopamine agonist, switching to the other if needed. Consider rotigotine if these are ineffective. [1]
- For orthostatic hypotension, review medicines that may contribute, including antihypertensives and diuretics. Consider midodrine, observing its contraindications and monitoring for supine hypertension. If midodrine is contraindicated, not tolerated or ineffective, consider fludrocortisone, taking account of its cardiac risk and drug interactions. [1]
- Ask about hallucinations, particularly visual, and delusions at reviews and after medicine changes. Perform a general medical evaluation and treat possible triggering conditions. Leave well-tolerated symptoms untreated. Reduce Parkinson's medicines that may have triggered symptoms, with attention to severity and withdrawal effects, but seek specialist advice before modifying therapy. [1]
- Consider quetiapine for hallucinations and delusions in people without cognitive impairment. If standard treatment is not effective, offer clozapine, which requires registration with a patient monitoring service. Quetiapine and clozapine need lower doses in Parkinson's disease than in other indications. Do not offer olanzapine. [1]
- In Parkinson's disease dementia, offer a cholinesterase inhibitor when dementia is mild or moderate, and consider one when it is severe. Consider memantine only if cholinesterase inhibitors are not tolerated or are contraindicated. [1]
- Consider drug treatment for drooling when non-drug approaches such as speech and language therapy are unavailable or ineffective. Options to consider include glycopyrronium bromide and referral for botulinum toxin A. Use other anticholinergics only when cognitive risk is minimal, preferring topical forms such as atropine where possible. [1]
Therapies, nutrition and neuroprotection
- Consider referring people in the early stages of Parkinson's disease to a physiotherapist, an occupational therapist and a speech and language therapist experienced in Parkinson's disease. Offer disease-specific physiotherapy for balance or motor function problems. Consider the Alexander Technique for people experiencing balance or motor function problems. Offer disease-specific occupational therapy for difficulties with daily living. Offer speech and language therapy for communication, swallowing or saliva problems, including swallowing-safety strategies such as EMST. [1]
- Consider dietitian referral. For people on levodopa with motor fluctuations, discuss moving most protein to the final main meal, without lowering total daily protein. Advise vitamin D supplementation. Do not offer creatine, and advise people to check over-the-counter supplements with a pharmacist or clinician first. [1]
- Do not use vitamin E for neuroprotection. Do not use co-enzyme Q10, dopamine agonists or MAO-B inhibitors as neuroprotective therapy outside clinical trials. [1]
Advanced disease and palliative care
- In advanced disease, offer best medical therapy, which may include intermittent apomorphine injection or continuous subcutaneous infusion. Do not offer deep brain stimulation when best medical therapy controls symptoms, but consider it when it does not. A technology appraisal recommends foslevodopa–foscarbidopa as an option for advanced levodopa-responsive disease with severe fluctuations and hyperkinesia or dyskinesia. This applies when available medicines are not working well enough and apomorphine or deep brain stimulation cannot be used or no longer control symptoms. [1]
- Offer opportunities to discuss prognosis. Offer oral and written information, and record that the discussion took place, covering topics such as advance care planning, ADRT, DNACPR orders and lasting power of attorney. When discussing palliative care, recognise that family members and carers may need different information from the person with Parkinson's disease. Consider palliative care team referral at any stage of the disease. [1]
Limitations and use
- Only the recommendations chapter was reviewed. Research recommendations, rationale and impact, update history and committee information were not included.
- Flowcharts and visual algorithms were available only as alternative text.
- Several drug uses were noted as off-label as of July 2017; current licensing status was not assessed. Examples include clonazepam, melatonin, fludrocortisone, quetiapine, glycopyrronium bromide, memantine and some cholinesterase inhibitors.
- Depression and dementia management are deferred to separate NICE guidelines. Foslevodopa–foscarbidopa and botulinum toxin for sialorrhoea are covered by separate technology appraisals not reviewed here.
- Advice refers to UK-specific bodies and processes (DVLA, MHRA, NHS England commissioning policy) that may not apply elsewhere.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Parkinson’s disease in adults
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 19 July 2017
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.